Cantor Fitzgerald Analysts Give Zoetis Inc. (NYSE:ZTS) a $75.00 Price Target
Zoetis Inc. (NYSE:ZTS) has been given a $75.00 price objective by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 24.51% from the company’s current price. Cantor Fitzgerald also issued estimates for Zoetis’ FY2017 earnings at $2.30 EPS.
Several other analysts also recently weighed in on ZTS. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $62.00 price objective on shares of Zoetis in a research report on Monday, August 7th. Deutsche Bank AG cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $65.00 price objective on the stock. in a research note on Tuesday, July 25th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research note on Friday, July 21st. Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company. Zoetis has an average rating of “Buy” and a consensus price target of $64.78.
Zoetis (ZTS) traded up 1.69% during midday trading on Monday, hitting $60.74. 1,091,038 shares of the stock traded hands. The company has a market cap of $29.71 billion, a PE ratio of 34.34 and a beta of 1.02. Zoetis has a one year low of $46.86 and a one year high of $63.85. The company’s 50-day moving average is $62.20 and its 200-day moving average is $58.00.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the business earned $0.49 EPS. Equities research analysts expect that Zoetis will post $2.34 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in Zoetis by 2,471.1% in the first quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock valued at $1,925,722,000 after buying an additional 34,679,064 shares during the last quarter. Morgan Stanley boosted its position in shares of Zoetis by 182.5% in the first quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock worth $780,119,000 after buying an additional 9,442,207 shares during the last quarter. Marshall Wace North America L.P. bought a new position in shares of Zoetis during the first quarter worth approximately $243,854,000. Alliancebernstein L.P. boosted its position in shares of Zoetis by 55.4% in the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock worth $646,905,000 after buying an additional 3,695,449 shares during the last quarter. Finally, Waddell & Reed Financial Inc. boosted its position in shares of Zoetis by 65.9% in the first quarter. Waddell & Reed Financial Inc. now owns 5,434,371 shares of the company’s stock worth $290,033,000 after buying an additional 2,157,803 shares during the last quarter. 92.70% of the stock is owned by institutional investors and hedge funds.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.